Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2003

View Archived Issues

Acceptable safety profile described for oral diflomotecan in solid tumors

Recombinant human angiostatin well tolerated in cancer patients

Avera licenses Novartis compound for depression

Encouraging preliminary phase II results for LyphoDerm

Watson acquires Amarin drug development subsidiary

Novel phosphate transport inhibitors discovered at Genzyme

New MAO-B inhibitors for use in AD and senile dementia identified at Roche

Altana Pharma claims novel iNOS inhibitors in recent patent

Fujisawa patent covers new PARP inhibitors and their use

Two series of GSK-3 inhibitors claimed in recent patent

BMS scientists develop new inhibitors of MMP, TACE and/or aggrecanase

Novel FTase inhibitors prepared and tested at Janssen

New pyrrole-based photosensitizers and their use in cancer therapy

European approval announced for Emtriva

Potent, direct inhibitor of Na+/Ca2+ exchange pathway

CVT-3146 studied as pharmacological stress agent in pivotal trial

FDA warns of Cypher Coronary Stent adverse events

SK-3530, a potent and selective PDE5 inhibitor in clinical testing for MED

Guilford acquires U.S. Aggrastat rights from Merck

SOLO Lexiva results show increase in HDL cholesterol in treatment-naive HIV patients

Oncolytics Biotech and NCI enter collaborative agreement for Reolysin

Encouraging topline results from phase III trials of cilansetron

Fast track designation for Tocosol Paclitaxel

Anti-EGFR antibody with ADCC-inducing activity

Cardioprotective K(ATP) channel openers designed by Korean team

Evidence of antiviral activity for ISIS-14803 in chronic hepatitis C

Therapeutic benefits reported for anakinra in osteoarthritis of the knee

Mechanism of anti-HBV activity of HepeX-B

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026